Abstract
Introduction
dosages (10). When accompanied by streptomycin, PAS therapy was associated with a 69 five year mortality of 19% (10). This rate can be compared with a mortality of 80% 70 reported for some series of XDR HIV-associated TB (11). 71
For nearly two decades a granular slow-release form of PAS (PASER ® granules, 72 para-aminosalicylic acid delayed release granules) has been available and has been 73 found to cause less intolerance in several studies in TB patients and healthy volunteers 74 (12, 13) . This formulation still provides PAS concentrations exceeding the MIC of PAS 75 when dosed at 4g twice daily. It was also shown that 4g once daily failed to maintain 76 concentrations above MIC over a 24 hour dosing interval (12, 13) . Although PAS has 77 been in use for more than 60 years, and was extensively studied, little is known about 78 the pharmacokinetics of PAS in HIV-infected patients and potential drug-drug 79 interactions of PAS with other co-administered second line TB drugs and antiretroviral 80 (ARV) medications and the currently available PAS formulation (PASER ® ) has been the 81 services in managing therapy in patients with MDR-TB and XDR-TB, as well as to 92 evaluate whether once daily dosing can provide PAS concentrations above MIC for the 93 greater part of a dosing interval. 94
We therefore explored PAS pharmacokinetics in adults with and without HIV 95 infection in a dose of 4g twice daily, but also later in a second study wherein patients 96 were randomized to receive either 4g PAS twice daily or 8g once daily. We aimed to 97 evaluate whether once daily dosing with a slow-release preparation might provide 98 satisfactory concentrations throughout a 24 hour dosing interval and whether there are 99 factors that may affect the pharmacokinetics of PAS. Given the large variety of possible 100 drug combinations to study in TB patients and those with HIV-infection, this study was 101 exploratory in nature and no a-priori evaluation of specific drug combinations for drug-102 drug interaction was planned. In this paper we summarize our findings regarding the 103 population pharmacokinetics (PK) of PAS and screening of concomitant medications for 104 possible effects on PAS disposition in our patients. 105 sex, weight, height, HIV antibody test results, serum creatinine, concomitant 114 medications and concurrent disease diagnosis were documented. 115
Patients were prescribed oral PAS (PASER® granules, para-aminosalicylic acid 116 delayed release granules, Jacobus Pharmaceutical, Princeton, NJ, USA). In the first 117 study, the subjects received 4g PAS twice daily on two occasions to evaluate 118 interoccasion variability, with at least 1 week elapsing between the two occasions. Their 119 blood samples were collected at pre-dose and 2, 3, 4, 5, 6, 8 and 12 hours post-dose. 120
The second study was a randomized cross-over study where patients received either 4g 121 PAS twice daily or an 8g PAS once daily regimen on the first occasion followed by the 122 alternative dosing scheme on the 2 nd occasion. During both studies samples were taken 123 only after patients had received PAS 4g twice daily for at least two weeks and patients 124 who entered in the crossover study received the relevant regimen for another eight days 125 before the pharmacokinetic study. Samples for pharmacokinetic analysis were collected 126 at pre-dose and 1, 2, 3, 4, 5, 6, 8 and 12 hours after 4g twice daily; and at pre-dose andassay as previously described (14) . The analysis of quality control samples reported 137 good reproducibility with coefficient of variation of ≤5% and accuracy with between-138 sample differences not exceeding 2.5%. The lower limit of quantification was 0.01 139 μg/mL. All of the observed drug concentrations were above this limit. 140
Pharmacokinetic Analysis. The nonlinear mixed-effects modeling of PAS disposition 141 in TB-HIV co-infected patients was performed using NONMEM (version 7.2) with first-142 order conditional estimation and with η interaction. The one-compartment model with 143 first-order absorption with lag time or transit compartment followed by first-order 144 absorption (15, 16) or mixed Michaelis-Menten and first-order absorption (17) were 145 explored for the steady-state concentration-time profiles of patients who were 146 administered once-daily 8g or twice-daily 4g PAS. The final structural model was 147 parameterized on the PK parameters: transit rate constant (K tr ) with 3 transit 148 compartments, apparent oral clearance (CL/F), and the apparent volume of distribution 149 (V/F). The relative bioavailability parameter (F) assumed the value of 1. Exponential 150 interindividual variability terms were included in the pharmacokinetic parameters. 151
Interoccasion variability was introduced to both the apparent oral clearance and transit 152 rate constant: 153
where represents the mean parameter value. and describe interindividual and 154 interoccasion (within an individual) variability and were assumed to be independently 155 and normally distributed, both with mean zero and variances and , respectively. 156
The subscript i represents the individual and j represents the occasion for the individual.
Dummy variables were introduced to distinguish separate occasions wherein 1 was 158 designated for the first occasion wherein individuals received the first 4g twice-daily, 2 159 was indicated for the second 4g twice-daily and 3 was used for the 8g once-daily dosing 160 regimen. All three occasions were consolidated to determine the interoccasion 161 variability. The residual variability, which is a composite of the other unexplained errors, 162 was estimated by a mixture of additive and proportional error model. 163
Covariates that were evaluated for their potential effect on PAS disposition 164 included the following: total body weight, age, HIV status, gender, race, and 165 comedications. The concomitant medications were evaluated individually for their effect 166 on PAS disposition. Dummy variables consisting of 0 and 1 were introduced for 167 absence or presence of drug, respectively. The hypothesis testing to discriminate 168 among alternative hierarchical structural models was based on the p-values for the 169 forward inclusion and backward elimination at 0.05 and 0.01, respectively. After the 170 covariate screening determined that EFV has a significant effect on PAS 171
pharmacokinetic, EFV effect was tested on the apparent oral clearance. The covariate 172 model for the EFV effect on the apparent oral clearance was based on 173
where is the typical value (TV) for the population CL/F in the absence of EFV 174 concomitant medication, is the exponential factor to adjust for the population CL/F in 175 concomitant EFV medication and represents the indicator function for the presence 176 or absence of concomitant EFV. Dose effect of EFV could not be evaluated as all 177 patients who received EFV had 600 mg oral once-daily dose. 178 HIV status of the individual was also evaluated. The three additional HIV-179 seropositive individuals who were not on ART containing EFV were included in the 180 category for HIV status. The evaluation process for the effect of HIV status on the 181 pharmacokinetic of PAS was similar to that which was carried out for EFV. 182
Given the exploratory nature of the study, model selection was based on 183 maximum likelihood statistics (defined as negative twice the log likelihood), goodness-184 of-fit and visual predictive checks (VPC; with 5000 simulated profiles). 185
A Monte Carlo Mapped Power (MCMP) analysis (18) Several dosing regimens were simulated with 5000 virtual subjects to determine 206 the probability of attaining the pharmacodynamic target: (1) 4g every 8 and 12 h; (2) 6g 207 every 12 and 24 h; (4) 8g once daily; and (5) 12g once daily. The target was attained 208 when 90% of the simulated fC min was greater than the MIC. The probability of target 209 attainment (PTA) was computed over a range of 2-fold incrementing MICs (range: 0.128 210 to 4 µg/mL). 211
Results

212
Patient Characteristics. The patients' characteristics and administration of 213 concomitant drugs are listed in tables 1 and 2. Forty-one patients were recruited in the 214 4g twice-daily study and 32 patients in the cross-over study; data from all 73 patients 215 were used in the analysis; 26% were HIV co-infected, 21% had XDR TB, and 79% MDR 216
TB. 217
The time-course of PAS concentrations was well described by a one-218 compartment disposition model with its absorption described by a 3-transit-compartment 219 in series (Figure 1 The MCMP analysis indicated that the sample size of 73 with 19 and 54 patients 236 receiving and not receiving EFV respectively for the covariate analysis had 95% and 237 88% power at p=0.05 and 0.01, respectively to detect differences in PAS 238 pharmacokinetics. Similarly, for an 80% power at significance level of p=0.05, 10 and 30 239 individuals on PAS with or without EFV respectively would be sufficient to detect the 240 EFV effect. Because of the exploratory and uncontrolled nature of the study there was 241 an unbalanced allocation of subjects in each treatment group. For this reason, a formal 242 bioequivalence-type analysis was not performed. Given the sample size, however, the 243 study was deemed sufficiently powered to detect pharmacokinetic interactions, andMCMP analysis indicated that the sample size of the present study was sufficient to 245 detect an EFV effect with a statistical power of 95%. The other demographic variables 246
were not influential factors of PAS pharmacokinetics. 247
Efavirenz Interaction with PAS. During the screening for drug-drug interaction, the 248 EFV effect in reducing PAS exposure was significant. The difference in objective 249 function value was 8.94 from the base model, which is significant at p=0.01 level. EFV 250 was associated with an approximately 52% increased PAS clearance in patients who 251 took this concurrent medication. The exponential coefficient for the effect of EFV on 252 PAS CL/F was 0.419, which translated to 1.52 in the linear scale (Table 3 ). The 253 estimated PAS AUCs over a day ) from the population PK analysis without and 254 with EFV were 875 ± 424 and 621 ± 295 mg.h/L in the 4g twice-daily and 889 ± 493 and 255 625 ± 338 mg.h/L in 8g once-daily, respectively. The HIV-infected patients on EFV had 256 an overall >30% reduction in PAS mean exposure. 257 (37.3%), respectively. The reduction in the PAS half-life in EFV co-medication group 267 indicated that EFV effect on PAS CL/F is more likely than its effect on PAS relative 268 bioavailability. There are some indications that EFV induction is primarily hepatic and 269
not intestinal (22). 270
Monte Carlo Simulations and Probability of Target Attainment. The plasma PAS 271 concentrations were simulated for several dosing regimens and the resulting exposure 272 parameters are summarized in Figure 4 . The top panels are the pharmacokinetic 273 parameters in virtual patients who had concomitant EFV whereas the lower panels are 274 for those without EFV. The increase in PAS clearance in patients who were co-275 administered EFV was reflected in lower plasma PAS concentrations and areas under 276 the concentration-time curve. In the computation of the free C min of PAS, the fraction 277 unbound is assumed to be 50% of the total drug concentration (19). There is an overall 278 >30% reduction in PAS exposure with EFV. These simulated profiles were used to 279 determine the probability of achieving free PAS levels greater than the MIC against M. 280 tuberculosis, as shown in Figure 5 . 281
The PTA was based on the free trough PAS concentration (fC min ) above the MICThe once-daily dosage regimens of 6g, 8g and even 12g are at risk of not 290 achieving PTA at MIC of 1 μg/mL. With the exception of 12g once-daily dosing without 291 EFV, PTA for the other remaining dosage regimens were below 90% ( Figure 5 middle  292 and right panels). The 5 th percentiles of free PAS trough concentrations in the once-293 daily dosing were below the 1 μg/mL for the three doses, regardless of whether EFV 294 was coadministered or not. 295
DISCUSSION
296
The most important findings of this study are that PAS concentrations are 297 reduced in HIV-infected TB patients and that concomitant administration of EFV likely 298 plays a role in this deficit. Our population pharmacokinetic model predicts a 52% 299 increase in PAS clearance. A corresponding reduction of 30% in mean PAS exposure 300 was observed in TB-HIV co-infected patients on EFV. To our knowledge, there has 301 been no in vitro or animal experiment to evaluate drug interactions between second-line 302 anti-tuberculosis and anti-retroviral therapies. 303
The mechanism of the drug-drug interaction between efavirenz and PAS remains 304 to be elucidated. PAS was recently shown to be a prodrug that acts as a metabolic 305 precursor of the folate biosynthetic pathway (23). More than 80% of absorbed PAS isphase I and phase II metabolic enzymes including induction of CYP3A4, 2B6, 2C19, 312 UGT1A1 2B7 and bile efflux transporters and inhibition of CYP3A5, 2C9, 2C19 and 313 UDP 1A4 and 1A9 (28-34) . The effect of efavirenz on CYP3A4 was previously shown to 314 be due to the activation of the human pregnane X receptor, which regulates the 315 CYP3A4 transcription (35). An average of 3-to 4-fold increase in CYP3A4 activity was 316 observed at 5 to 10 μM efavirenz concentration (35). Consequently, CYP3A4 substrates 317 when administered with efavirenz resulted in a reduction in plasma levels of these drugs 318 (36-38). EFV was thought to only affect the hepatic CYP3A4 (22). One study indicated 319 that there may be some association between efavirenz systemic exposure and NAT2 320 genotypes as risk factors of liver injury in TB-HIV patients (39). Even though their study 321
was not designed to evaluate efavirenz effect on NAT2 enzymes, we hypothesize that 322 modulation of NAT2 activities by efavirenz may contribute to toxicity of drugs and 323 agents that are metabolized by NAT2. Given the wide variety of drug metabolic 324 enzymes that were shown to be affected by efavirenz, it is likely that the increase in 325 than 1 μg/mL free PAS concentration was unlikely for the once-daily dosage regimens, 358 except for the 12g PAS without EFV concomitantly administered. Our study has shown 359 that the 4g twice-daily PAS dosage achieves a 90% PTA for fC min >1 μg/mL even with 360 concurrent EFV in HIV-positive patients with TB. However, the once-daily dosing even 361 at 12g is not compatible with EFV concurrent medication. We did not simulate higher 362 doses so as not to go above the total daily dose recommended in the product's package 363 insert. 364
Despite the current conviction that PAS is bacteriostatic there is evidence that 365 PAS has bactericidal effects at higher doses probably associated with peak 366 concentrations. Thus Jindani et al (1980) studied the early bactericidal activity (EBA) of 367 anti-TB agents by quantifying the serial reduction of colony forming units (cfu) of M. 368 tuberculosis in sputum of pulmonary TB patients and reported that at a single dose of 369 15 g in the first two treatment days, PAS caused a fall in CFU per mL sputum per day 370 of 0.25 log 10 /mL, a rank that is only preceded by isoniazid (48). In a study of 371 streptomycin resistance prevention, the evaluation of PAS daily dosages of 5, 10 or 20 372 g divided in four doses showed that following four months of treatment with the highest 373 dosage of 20 g PAS in divided doses only 4% of patients developed streptomycin 374 resistance but the proportion increased to 21% and 47% following lower PAS dosages 375 of 10 g or 5 g daily (49). In a subsequent study following the introduction of the more 376 powerful drug isoniazid, it was found that a daily PAS dosage of 10 g was adequate to 377 prevent the development of resistance to isoniazid (50). An early in vitro study also 378 reported that low PAS concentrations only delayed the emergence of PAS resistance, 379 but that higher concentrations suppressed the growth of resistant mutants (51). Thereis also recent evidence that PAS resistance occurs over a wide range of MIC (52), some 381 of which are well within the range of the peak concentration achieved by many of our 382 patients receiving 8 g once daily. The MIC of PAS-resistant M. tuberculosis complex 383 strains containing mutations in the thyA gene, which encodes enzymes of the folate 384 pathway (53), ranged from 8 to over 128 μg/mL (52). The pharmacokinetic-385 pharmacodynamic index of PAS is still debatable as to whether the improved action of 386 PAS in preventing resistance in companion drugs was due to the maintenance of 387 concentrations above MIC or to the higher peak concentrations. In the case of isoniazid 388 when administered with the purpose of preventing resistance development of other 389 companion TB drugs, its pharmacokinetic-pharmacodynamic index is related to the 390 peak concentrations (54). 391
In conclusion, this study demonstrates a possible effect of EFV on the 392 to a PTA value of 90%, which corresponds to the success probabilities. 609 
